EXOSC1

Across TCGA pan-cancer cohorts, EXOSC1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EXOSC1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXOSC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXOSC1 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and LUAD are the cancer types where EXOSC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.215	0.763	.006	16	view →
CCRCC	OS	Quartile	III,IV	0.504	0.918	.010	10	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

EXOSC1–PDAC (OS)

Open the PDAC breakdown →